London, Feb 6, 2026, 09:28 GMT — Regular session
- Haleon shares slipped roughly 0.7% in early trading, underperforming the softer UK market.
- Ahead of Haleon’s full-year results due Feb. 25, traders are adjusting their positions.
- Renewed tech jitters and a dovish-leaning Bank of England vote sparked broader risk-off moves.
Shares of Haleon PLC slipped around 0.7% to 396.4 pence in early London trading on Friday, weighed down as the broader market edged lower. Investors are gearing up for the consumer health firm’s full-year earnings due later this month.
This move takes on extra weight as Haleon approaches a crucial earnings report amid jittery markets. When liquidity dries up and sentiment wavers, pricing shifts driven by results tend to happen faster. On top of that, expectations for UK rate cuts have shifted once more following the Bank of England’s recent vote.
London shares slipped at the open, with the FTSE 100 shedding around 0.3% soon after the bell. Investors remained on edge following a tough day for tech and software stocks in the U.S.
European stocks edged lower as the STOXX 600 slipped 0.2% in early trading. Tech shares took a hit, dragged down by news around corporate spending and earnings that dampened risk appetite.
On Thursday, the Bank of England kept interest rates steady, in a tighter-than-expected 5-4 vote. Sterling dropped, and short-term yields fell as traders shifted toward pricing in rate cuts later this year. “UK yields could correct … and that should lead to further weakness in the pound,” said Elias Haddad, senior markets strategist at Brown Brothers Harriman. https://www.reuters.com/world/uk/view-bank-england-leaves-rates-unchanged-sterling-falls-2026-02-05/
Haleon faces a key milestone on Feb. 25, with full-year 2025 results set to be released. The company also plans to issue a first-quarter trading update on April 29.
Investors are eyeing any update on sales growth and margins, along with new details on “organic” growth — which excludes currency effects and acquisitions. Haleon last reported quarterly results in late October.
The company signaled internal shifts earlier this year. In January, it announced plans to evolve its operating model, promising more details with the Feb. 25 earnings. CEO Brian McNamara said these moves aim to make Haleon “a simpler and more agile and efficient organisation.” https://www.haleon.com/news/press-releases/financial/2026/haleon-operating-model-evolution-2026
Haleon, the company behind Sensodyne toothpaste, Panadol pain relief, and Voltaren, went public in 2022 following its spin-off from GSK’s consumer health division.
Risks remain. A misstep in execution—whether in reshuffling teams or stabilizing marketing and supply chains—could hit fast in categories where consumers are trading down. The stock offers minimal cushion if market volatility persists through earnings.
Next on the calendar: Haleon’s full-year results for Feb. 25, along with any 2026 guidance clues. The first-quarter trading update comes next on April 29.
Related articles: Stock Market
